Scholar Rock Holding Corporation (NASDAQ:SRRK) Insider Sells $828,833.04 in Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK - Get Free Report) insider Mo Qatanani sold 24,066 shares of the firm's stock in a transaction on Tuesday, July 8th. The shares were sold at an average price of $34.44, for a total value of $828,833.04. Following the sale, the insider directly owned 115,495 shares of the company's stock, valued at $3,977,647.80. This represents a 17.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Scholar Rock Stock Down 1.8%

Shares of Scholar Rock stock traded down $0.68 during trading on Friday, reaching $37.44. The stock had a trading volume of 687,816 shares, compared to its average volume of 1,162,312. The company has a market capitalization of $3.55 billion, a price-to-earnings ratio of -14.80 and a beta of 0.33. The stock has a fifty day moving average price of $32.69 and a two-hundred day moving average price of $35.31. Scholar Rock Holding Corporation has a 52 week low of $6.76 and a 52 week high of $46.98. The company has a current ratio of 10.25, a quick ratio of 10.25 and a debt-to-equity ratio of 0.16.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same period last year, the company posted ($0.59) earnings per share. Sell-side analysts predict that Scholar Rock Holding Corporation will post -2.42 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Scholar Rock by 42.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 135,231 shares of the company's stock valued at $5,845,000 after purchasing an additional 40,436 shares during the last quarter. GAMMA Investing LLC boosted its position in Scholar Rock by 3,824.9% during the first quarter. GAMMA Investing LLC now owns 30,928 shares of the company's stock valued at $962,000 after purchasing an additional 30,140 shares during the last quarter. Vanguard Group Inc. boosted its position in Scholar Rock by 17.6% during the fourth quarter. Vanguard Group Inc. now owns 4,743,482 shares of the company's stock valued at $205,013,000 after purchasing an additional 708,817 shares during the last quarter. Blackstone Inc. acquired a new position in Scholar Rock during the fourth quarter valued at approximately $910,000. Finally, Raymond James Financial Inc. acquired a new position in Scholar Rock during the fourth quarter valued at approximately $2,625,000. 91.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Lifesci Capital raised Scholar Rock to a "strong-buy" rating in a research note on Tuesday, June 3rd. Wedbush reissued an "outperform" rating and issued a $50.00 target price on shares of Scholar Rock in a research note on Wednesday, June 18th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $42.67.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.